Royalty Pharma (RPRX) Common Equity (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Common Equity data on file, last reported at $9.9 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 1.63% year-over-year to $9.9 billion; the trailing twelve-month figure through Mar 2026 stood at $9.9 billion (up 1.63% YoY), and the FY2025 full-year result was $9.7 billion, down 6.07% from the prior year.
• Common Equity grew to $9.9 billion in Q1 2026, from $9.7 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $10.4 billion in Q3 2022 to a low of $9.5 billion in Q2 2025.
• A 5-year average of $9.9 billion and a median of $9.8 billion in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity fell 7.98% in 2023 and rose 7.03% in 2024, its largest moves.
• Tracing RPRX's Common Equity over 5 years: stood at $9.5 billion in 2022, then rose by 5.87% to $10.1 billion in 2023, then rose by 2.56% to $10.3 billion in 2024, then fell by 6.07% to $9.7 billion in 2025, then climbed by 2.28% to $9.9 billion in 2026.
• Business Quant data shows RPRX's Common Equity at $9.9 billion in Q1 2026, $9.7 billion in Q4 2025, and $9.6 billion in Q3 2025.